Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

San Diego newco heads for clinic with allogeneic NK cells, series A led by 5AM, venBio and RA

A U.S. investor syndicate and management team have set up Artiva, bringing to San Diego allogeneic natural killer cell technology from South Korean company GC LabCell -- including one program due to enter the clinic this year.

Artiva Biotherapeutics Inc. will have exclusive rights outside Asia-Pacific territories to core NK cell therapy technologies including manufacturing expertise, as well as an initial pipeline, from Green Cross LabCell Corp. (KOSDAQ:144510).

Artiva’s launch

Read the full 688 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers